Skip to main content

2 Result(s)

within Philipp Krapf Remove this filter Cardiac Imaging Remove this filter

and

  1. Article

    Open Access

    Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer

    In 2022, the American Food and Drug Administration and the European Medicines Agency approved [177Lu]Lu-PSMA-617 (PLUVICTO™, Novartis AG, Basel, Switzerland) for radionuclide therapy with prostate-specific membra...

    Jan Heilinger, Jasmin Weindler, Katrin Sabine Roth, Philipp Krapf… in EJNMMI Research (2023)

    Download PDF (1299 KB) View Article

  2. Article

    Open Access

    Biodistribution and radiation dosimetry of [18F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer

    We investigated the whole-body distribution and the radiation dosimetry of [18F]-JK-PSMA-7, a novel 18F-labeled PSMA-ligand for PET/CT imaging of prostate cancer.

    Melanie Hohberg, Carsten Kobe, Philipp Krapf, Philipp Täger… in EJNMMI Research (2019)

    Download PDF (3131 KB) View Article